Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

2014 ◽  
Vol 20 (2) ◽  
pp. 332-337 ◽  
Author(s):  
Yoichiro Yoshida ◽  
Seiichiro Hoshino ◽  
Naoya Aisu ◽  
Masayasu Naito ◽  
Syu Tanimura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Median Cubital Vein ◽  
Colorectal Cancer Patients

scholarly journals Administration of Chemotherapy Via Median Cubital Vein Without Central Venous Access Port for Colorectal Cancer

2014 ◽  
Vol 25 ◽  
pp. v93
Author(s):  
Yoichiro Yoshida ◽  
Seiichiro Hoshino ◽  
Naoya Aisu ◽  
Masayasu Naito ◽  
Syu Tanimura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Central Venous Access ◽  
Venous Access ◽  
Central Venous ◽  
Access Port ◽  
Median Cubital Vein ◽  
Venous Access Port

Administration of chemotherapy via median cubital vein without implantable central venous access port for metastatic colorectal cancer: Port-free chemotherapy.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 651-651 ◽  
Author(s):  
Yoichiro Yoshida ◽  
Naoya Aisu ◽  
Masayasu Naito ◽  
Syu Tanimura ◽  
Takamitsu Sasaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Central Venous Access ◽  
Central Venous ◽  
Access Port ◽  
Port Implantation ◽  
Median Cubital Vein ◽  
Port Systems ◽  
Grade 3 ◽  
Vascular Pain

651 Background: Repeated venous punctures are usually required in cancer patients for application of chemotherapy. Central venous catheters and implantable port systems have substantially facilitated the problem of vascular access. Safe and easy-to-handle port systems have become an integral part of daily clinical routine in oncology. However, there are several serious complications associated with central venous ports (CV-ports). With the recent development of capecitabine plus oxaliplatin (XELOX) therapy involving oral administration of drug preparations, etc., implantation of a CV-port can be avoided. The present study was undertaken to evaluate the safety of administration of chemotherapy via median cubital vein without CV port for metastatic colorectal cancer. Methods: The study included 144 patients who received XELOX + bevacizumab (BV) therapy and XELOX therapy for metastatic colorectal cancer without implantation of a CV-port. Results: Eighty-five patients experienced vascular pain, but it was transient. The drip infusion route had to be switched to the opposite side because of vascular pain in only 1 of the 144 patients. No patients required CV-port implantation or postponement of treatment due to adverse events caused by administration of the drug via the peripheral vein. Grade 3 or higher hemotoxicity was noted in 12.5%, and grade 3 or higher nonhematological toxicity was noted in 17.4%. Conclusions: We may be able to perform port-free-chemotherapy via median cubital vein for patients with colorectal cancer. We can avoid the serious complications associated with CV-port.

Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)

1996 ◽  
Vol 75 (02) ◽  
pp. 251-253 ◽  
Author(s):  
Manuel Monreal ◽  
Antoni Alastrue ◽  
Miquel Rull ◽  
Xavier Mira ◽  
Jordi Muxart ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Upper Extremity ◽  
Statistical Significance ◽  
Central Venous Access ◽  
Venous Access ◽  
Bleeding Complications ◽  
Fisher Exact Test ◽  
Central Venous ◽  
True Incidence ◽  
Venous Access Devices

SummaryCentral venous access devices are often essential for the administration of chemotherapy to patients with malignancy, but its use has been associated with a number of complications, mainly thrombosis. The true incidence of upper extremity deep vein thrombosis (DVT) in this setting is difficult to estimate since there are very few studies in which DVT diagnosis was based on objective tests, but its sequelae include septic thrombophlebitis, loss of central venous access and pulmonary embolism.We performed an open, prospective study in which all cancer patients who underwent placement of a long-term Port-a-Cath (Pharmacia Deltec Inc) subclavian venous catheter were randomized to receive or not 2500 IU sc of Fragmin once daily for 90 days. Venography was routinely performed 90 days after catheter insertion, or sooner if DVT symptoms had appeared. Our aims were: 1) to investigate the effectiveness of low doses of Fragmin in preventing catheter-related DVT; and 2) to try to confirm if patients with high platelet counts are at a higher risk to develop subclavian DVT, as previously suggested.On the recommendation of the Ethics Committee, patient recruitment was terminated earlier than planned: DVT developed in 1/16 patients (6%) taking Fragmin and 8/13 patients (62%) without prophylaxis (Relative Risk 6.75; 95% Cl: 1.05-43.58; p = 0.002, Fisher exact test). No bleeding complications had developed. As for prediction of DVT, there was a tendency towards a higher platelet count in those patients who subsequently developed DVT, but differences failed to reach any statistical significance (286 ±145 vs 207 ±81 X 109/1; p = 0.067). According to our experience, Fragmin at the dosage used proved to be both effective and safe in these patients.

A Psychometric Validation of the Decisional Conflict Scale in Italian Cancer Patients Scheduled for Insertion of Central Venous Access Devices

2020 ◽  
Vol 40 (10) ◽  
pp. 5583-5592
Author(s):  
MARIA ROSARIA ESPOSITO ◽  
ASSUNTA GUILLARI ◽  
FRANCESCO GIANCAMILLI ◽  
TERESA REA ◽  
MICHELA PIREDDA ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Central Venous Access ◽  
Venous Access ◽  
Decisional Conflict ◽  
Psychometric Validation ◽  
Central Venous ◽  
Decisional Conflict Scale ◽  
Venous Access Devices ◽  
Conflict Scale

scholarly journals Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2410
Author(s):  
Chungyeop Lee ◽  
In-Ja Park ◽  
Kyung-Won Kim ◽  
Yongbin Shin ◽  
Seok-Byung Lim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Medical Center ◽  
The Body ◽  
Term Survival ◽  
Postoperative Changes ◽  
Asan Medical ◽  
Colorectal Cancer Patients

The effect of perioperative sarcopenic changes on prognosis remains unclear. We conducted a retrospective cohort study with 2333 non-metastatic colorectal cancer patients treated between January 2009 and December 2012 at the Asan Medical Center. The body composition at diagnosis was measured via abdominopelvic computed tomography (CT) using Asan-J software. Patients underwent CT scans preoperatively, as well as at 6 months–1 year and 2–3 years postoperatively. The primary outcome was the association between perioperative sarcopenic changes and survival. According to sarcopenic criteria, 1155 (49.5%), 890 (38.2%), and 893 (38.3%) patients had sarcopenia preoperatively, 6 months–1 year, and 2–3 years postoperatively, respectively. The 5-year overall survival (OS) (95.8% vs. 92.1%, hazard ratio (HR) = 2.234, p < 0.001) and 5-year recurrence-free survival (RFS) (93.2% vs. 86.2%, HR = 2.251, p < 0.001) rates were significantly lower in patients with preoperative sarcopenia. Both OS and RFS were lower in patients with persistent sarcopenia 2–3 years postoperatively than in those who recovered (OS: 96.2% vs. 90.2%, p = 0.001; RFS: 91.1% vs. 83.9%, p = 0.002). In multivariate analysis, postoperative sarcopenia was confirmed as an independent factor associated with decreased OS and RFS. Pre- and postoperative sarcopenia and changes in the condition during surveillance were associated with oncological outcomes.

Sign in / Sign up

Export Citation Format

Share Document